Evidence map›Paper›PMID 38221788›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2024

Design, synthesis, and bioevaluation of 1

Chao Wang, Yujing Zhang, Shanbo Yang, Lingyu Shi, Rong Rong, Tingting Zhang, Yudong Wu, Dongming Xing

Abstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Novel 6-aryl-1-(3,4,5-trimethoxyphenyl)-1Journal of enzyme inhibition and medicinal chemistry · 2026
    Article
  3. Conformationally constrained 6‑aryl‑1‑(3,4,5‑trimethoxyphenyl)-1Journal of enzyme inhibition and medicinal chemistry · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chao WangCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Yujing ZhangThe Affiliated Cardiovascular Hospital of Qingdao University, Qingdao University, Qingdao, China.
Shanbo YangCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Lingyu ShiCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Rong RongYantai Key laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Yantai, China.
Tingting ZhangCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Yudong WuCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Dongming XingCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new series of 1

Indexed as

Antineoplastic AgentsColchicineBinding SitesCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHeLa CellsHumansMolecular Docking SimulationPyridinesStructure-Activity RelationshipTubulinTubulin ModulatorsAntineoplastic AgentsColchicinePyridinesTubulinTubulin ModulatorsTubulin combreastatin A-4 restriction configuration 1H-pyrrolo[32-c]pyridine molecular docking

Identifiers

PMID38221788
PMCPMC10791102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.